Age and albumin D site-binding protein control tissue plasminogen activator levels: Neurotoxic impact

Brain

Volumn 132, Issue 8, 2009, Pages 2219-2230

  Roussel, Benoit D ^a,b   MacRez, Richard ^a,b   Jullienne, Amandine ^a,b   Agin, Vronique ^a,b   Maubert, Eric ^a,b   Dauphinot, Luce ^c   Potier, Marie Claude ^c   Plawinski, Laurent ^a,b   Castel, Herv ^a,b   Hommet, Yannick ^a,b   Munuera, Josep ^d   Montaner, Joan ^e   Yepes, Manuel ^f   Ali, Carine ^a,b   Vivien, Denis ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c Brain Plasticity Unit   (France)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ageing; Albumin D site binding protein; Neurovascular unit; Stroke; Tissue type plasminogen activator

Indexed keywords

ALBUMIN D SITE BINDING PROTEIN; ALTEPLASE; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; BRAIN PROTEIN; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGULATOR PROTEIN; SHORT HAIRPIN RNA; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG MECHANISM; ENZYMATIC ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXCITOTOXICITY; FEMALE; FETUS; GENE EXPRESSION; GROUPS BY AGE; HUMAN; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION REGULATION; ZYMOGRAPHY;

AGED; AGED, 80 AND OVER; AGING; ANIMALS; BRAIN; BRAIN ISCHEMIA; CELL DEATH; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; MIDDLE AGED; N-METHYLASPARTATE; NEURONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE PLASMINOGEN ACTIVATOR; TRANSCRIPTION FACTORS;

EID: 67749147230     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awp162     Document Type: Article

References (49)

1. Ahn JD, Morishita R, Kaneda Y, Kim HJ, Kim YD, Lee HJ, et al. Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo. Gene Ther 2004; 11: 916-23.
2. An J, Zhang C, Polavarapu R, Zhang X, Zhang X, Yepes M. Tissue-type plasminogen activator and the low density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain. Blood 2008; 112: 2787-94.
3. Bambauer KZ, Johnston SC, Bambauer DE, Zivin JA. Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol 2006; 63: 661-4.
4. Benchenane K, Berezowski V, Ali C, Fernández-Monreal M, Ló pez-Atalaya JP, Brillault J, et al. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 2005a; 111: 2241-9.
5. Benchenane K, Berezowski V, Ferná ndez-Monreal M, Brillault J, Valable S, Dehouck MP, et al. Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process. Stroke 2005b; 36: 1065-70.
6. Benchenane K, Ló pez-Atalaya JP, Fernández-Monreal M, Touzani O, Vivien D. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci 2004; 27: 155-60.
7. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z, et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006; 12: 1278-85.
8. Davis M, Mendelow AD, Perry RH, Chambers IR, James OF. Experimental stroke and neuroprotection in the aging rat brain. Stroke 1995; 26: 1072-8.
9. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuro-protection. Nat Med 2003; 9: 1173-9.
10. Engelter ST, Provenzale JM, Petrella JR, DeLong DM, Alberts MJ. Infarct volume on apparent diffusion coefficient maps correlates with length of stay and outcome after middle cerebral artery stroke. Cerebrovasc Dis 2003; 15: 188-91.
11. Fernández-Monreal M, Ló pez-Atalaya JP, Benchenane K, Cacquevel M, Dulin F, Le Caer JP, et al. Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling. J Biol Chem 2004; 279: 50850-6.
12. Fotheringham AP, Davies CA, Davies I. Oedema and glial cell involvement in the aged mouse brain after permanent focal ischaemia. Neuropathol Appl Neurobiol 2000; 26: 412-23.
13. Gachon F, Fonjallaz P, Damiola F, Gos P, Kodama T, Zakany J, et al. The loss of circadian PAR bZip transcription factors results in epilepsy. Genes Dev 2004; 18: 1397-412.
14. Golfier G, Dang MT, Dauphinot L, Graison E, Rossier J, Potier MC. VARAN: a web server for variability analysis of DNA microarray experiments. Bioinformatics 2004; 20: 1641-3.
15. Jaramillo A, Gó ngora-Rivera F, Labreuche J, Hauw JJ, Amarenco P. Predictors for malignant middle cerebral artery infarctions: a postmortem analysis. Neurology 2006; 66: 815-20.
16. Khatib ZA, Inaba T, Valentine M, Look AT. Chromosomal localization and cDNA cloning of the human DBP and TEF genes. Genomics 1994; 23: 344-51.
17. Kidwell CS, Latour L, Saver JL, Alger JR, Starkman S, Duckwiler G, et al. Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis 2008; 25: 338-43.
18. Klugmann M, Leichtlein CB, Symes CW, Klaussner BC, Brooks AI, Young D, et al. A novel role of circadian transcription factor DBP in hippocampal plasticity. Mol Cell Neurosci 2006; 31: 303-14.
19. Le Brigand K, Russell R, Moreilhon C, Rouillard JM, Jost B, Amiot F, et al. An open-access long oligonucleotide microarray resource for analysis of the human and mouse transcriptomes. Nucleic Acids Res 2006; 34: e87.
20. Lee SY, Kim HJ, Lee WJ, Joo SH, Jeon SJ, Kim JW, et al. Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide-stimulated rat primary astrocytes. Neurochem Res 2008; 33: 2324-34.
21. Liu D, Cheng T, Guo H, Fernández JA, Griffin JH, Song X, et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004; 10: 1379-83.
22. Lopez-Molina L, Conquet F, Dubois-Dauphin M, Schibler U. The DBP gene is expressed according to a circadian rhythm in the suprachias-matic nucleus and influences circadian behavior. EMBO J 1997; 16: 6762-71.
23. McGuire PG, Seeds NW. Degradation of underlying extracellular matrix by sensory neurons during neurite outgrowth. Neuron 1990; 4: 633-42.
24. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107: 598-603.
25. Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 1999; 99: 2440-4.
26. Nakayama H, Jørgensen HS, Raaschou HO, Olsen TS. The influence of age on stroke outcome. The Copenhagen Stroke Study. Stroke 1994; 25: 808-13.
27. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7: 59-64.
28. Osborne KA, Shigeno T, Balarsky AM, Ford I, McCulloch J, Teasdale GM, et al. Quantitative assessment of early brain damage in a rat model of focal cerebral ischaemia. J Neurol Neurosurg Psychiatry 1987; 50: 402-10.
29. Pawlak R, Melchor JP, Matys T, Skrzypiec AE, Strickland S. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci USA 2005; 102: 443-8.
30. Petcu EB, Sfredel V, Platt D, Herndon JG, Kessler C, Popa-Wagner A. Cellular and molecular events underlying the dysregulated response of the aged brain to stroke: a mini-review. Gerontology 2008; 54: 6-17.
31. Popa-Wagner A, Badan I, Vintilescu R, Walker L, Kessler C. Premature cellular proliferation following cortical infarct in aged rats. Rom J Morphol Embryol 2007; 27: 215-28.
32. Poppe AY, Hill MD. Acute ischaemic stroke in patients aged 80 years and older: focus on the tolerability of thrombolytic agents. Drugs Aging 2008; 25: 95-103.
33. Rosell A, Alvarez-Sabín J, Arenillas JF, Rovira A, Delgado P, Ferná ndez-Cadenas I, et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 2005; 36: 1415-20.
34. Samson AL, Medcalf RL. Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron 2006; 50: 673-8.
35. Schmoll H, Badan I, Fischer B, Wagner AP. Dynamics of gene expression for immediate early- and late genes after seizure activity in aged rats. Arch Gerontol Geriatr 2001; 32: 199-218.
36. Schnell SA, Staines WA, Wessendorf MW. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem 1999; 47: 719-30.
37. Shapira S, Sapir M, Wengier A, Grauer E, Kadar T. Aging has a complex effect on a rat model of ischemic stroke. Brain Res 2002; 925: 148-58.
38. Shin CY, Kundel M, Wells DG. Rapid, activity-induced increase in tissue plasminogen activator is mediated by metabotropic glutamate receptor-dependent mRNA translation. J Neurosci 2004; 24: 9425-33.
39. Siao CJ, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 2002; 22: 3352-8.
40. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008; 14: 731-7.
41. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-7.
42. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995; 377: 340-4.
43. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-21.
44. Wang L, Kittaka M, Sun N, Schreiber SS, Zlokovic BV. Chronic nicotine treatment enhances focal ischemic brain injury and depletes free pool of brain microvascular tissue plasminogen activator in rats. J Cereb Blood Flow Metab 1997; 17: 136-46.
45. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998; 4: 228-31.
46. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004; 35: 2726-2730.
47. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci 2009; 32: 48-55.
48. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003; 112: 1533-40.
49. Zlokovic BV, Wang L, Sun N, Haffke S, Verrall S, Seeds NW, et al. Expression of tissue plasminogen activator in cerebral capillaries: possible fibrinolytic function of the blood-brain barrier. Neurosurgery 1995; 37: 955-61.